Estimating The Drug Treatment Cost of Breast Cancer

Research output: Contribution to journalConference articleAcademicpeer-review

2 Citations (Scopus)
25 Downloads (Pure)

Abstract

Objectives
Overall treatment costs in oncology are increasing rapidly due to the increasing availability of expensive drugs. Comparing the costs of currently used drugs and assessing the cost-effectiveness of new drugs requires a transparent overview of actual breast cancer treatment prices. As such an overview is lacking, this study aims to synthesize evidence on the reimbursement and costs to estimate the total treatment cost of expensive breast cancer drugs for the Netherlands.

Methods
Evidence on the approval, reimbursement and list prices of expensive breast cancer drugs was identified from the Dutch Administrative Health Authority (ZINL). Data on the average length of treatment and dosing schedules was obtained from European Parliament Assessment Reports (EPARs) or ZINL reports. All evidence was aggregated in the estimation of actual treatment cost.

Results
In the Netherlands, 31 breast cancer drugs are approved (available in 41 different forms). Based on drug list prices Pertuzumab, Trastuzumab Emtansine and Trastuzumab are the most expensive drugs. For 17/41 (41.5%), no evidence on the average treatment length was available in EPARs or ZINL reports. Comparing list prices to the estimated treatment cost per patient resulted in substantial differences in the ranking of expensiveness of the drugs. Overall, estimated treatment costs were highest for Bevacizumab, Pertuzumab and Trastuzumab Emtansine.

Conclusions
Estimating treatment costs is far from trivial, given the wide range of evidence sources that need to be synthesized. This complicates rapid and transparent assessment of actual cancer drug treatment cost, which is necessary to focus strategies aiming to limit the increasing healthcare costs. Differences exist in list prices within countries and between countries, thereby influencing the corresponding estimated treatment costs and resulting in list prices having limited value in this context. Therefore, extending standardization in presenting information on costs per cancer drug and implementing real world price estimates in such calculations is highly recommended.
Original languageEnglish
Pages (from-to)A430-A431
JournalValue in health
Volume20
Issue number9
DOIs
Publication statusPublished - Sep 2017
EventISPOR 20th Annual European Congress 2017 - Scottish Event Campus, Glasgow, United Kingdom
Duration: 4 Nov 20178 Nov 2017
Conference number: 20
https://www.ispor.org/Event/Index/2017Glasgow

Fingerprint

Drug Costs
Health Care Costs
Breast Neoplasms
Pharmaceutical Preparations
Costs and Cost Analysis
Netherlands
Cost-Benefit Analysis
Neoplasms
Appointments and Schedules
Therapeutics
Health

Keywords

  • breast cancer
  • drugs
  • treatment cost
  • Evidence
  • health economics

Cite this

@article{876bf5fbed7a4c90809252a2beab03e2,
title = "Estimating The Drug Treatment Cost of Breast Cancer",
abstract = "ObjectivesOverall treatment costs in oncology are increasing rapidly due to the increasing availability of expensive drugs. Comparing the costs of currently used drugs and assessing the cost-effectiveness of new drugs requires a transparent overview of actual breast cancer treatment prices. As such an overview is lacking, this study aims to synthesize evidence on the reimbursement and costs to estimate the total treatment cost of expensive breast cancer drugs for the Netherlands.MethodsEvidence on the approval, reimbursement and list prices of expensive breast cancer drugs was identified from the Dutch Administrative Health Authority (ZINL). Data on the average length of treatment and dosing schedules was obtained from European Parliament Assessment Reports (EPARs) or ZINL reports. All evidence was aggregated in the estimation of actual treatment cost.ResultsIn the Netherlands, 31 breast cancer drugs are approved (available in 41 different forms). Based on drug list prices Pertuzumab, Trastuzumab Emtansine and Trastuzumab are the most expensive drugs. For 17/41 (41.5{\%}), no evidence on the average treatment length was available in EPARs or ZINL reports. Comparing list prices to the estimated treatment cost per patient resulted in substantial differences in the ranking of expensiveness of the drugs. Overall, estimated treatment costs were highest for Bevacizumab, Pertuzumab and Trastuzumab Emtansine.ConclusionsEstimating treatment costs is far from trivial, given the wide range of evidence sources that need to be synthesized. This complicates rapid and transparent assessment of actual cancer drug treatment cost, which is necessary to focus strategies aiming to limit the increasing healthcare costs. Differences exist in list prices within countries and between countries, thereby influencing the corresponding estimated treatment costs and resulting in list prices having limited value in this context. Therefore, extending standardization in presenting information on costs per cancer drug and implementing real world price estimates in such calculations is highly recommended.",
keywords = "breast cancer, drugs, treatment cost, Evidence, health economics",
author = "Berghuis, {Anne Margreet Sofie} and Hendrik Koffijberg and L.W.M.M. Terstappen and Stefan Sleijfer and IJzerman, {Maarten Joost}",
year = "2017",
month = "9",
doi = "10.1016/j.jval.2017.08.189",
language = "English",
volume = "20",
pages = "A430--A431",
journal = "Value in health",
issn = "1098-3015",
publisher = "Elsevier",
number = "9",

}

Estimating The Drug Treatment Cost of Breast Cancer. / Berghuis, Anne Margreet Sofie; Koffijberg, Hendrik ; Terstappen, L.W.M.M.; Sleijfer, Stefan; IJzerman, Maarten Joost.

In: Value in health, Vol. 20, No. 9, 09.2017, p. A430-A431.

Research output: Contribution to journalConference articleAcademicpeer-review

TY - JOUR

T1 - Estimating The Drug Treatment Cost of Breast Cancer

AU - Berghuis, Anne Margreet Sofie

AU - Koffijberg, Hendrik

AU - Terstappen, L.W.M.M.

AU - Sleijfer, Stefan

AU - IJzerman, Maarten Joost

PY - 2017/9

Y1 - 2017/9

N2 - ObjectivesOverall treatment costs in oncology are increasing rapidly due to the increasing availability of expensive drugs. Comparing the costs of currently used drugs and assessing the cost-effectiveness of new drugs requires a transparent overview of actual breast cancer treatment prices. As such an overview is lacking, this study aims to synthesize evidence on the reimbursement and costs to estimate the total treatment cost of expensive breast cancer drugs for the Netherlands.MethodsEvidence on the approval, reimbursement and list prices of expensive breast cancer drugs was identified from the Dutch Administrative Health Authority (ZINL). Data on the average length of treatment and dosing schedules was obtained from European Parliament Assessment Reports (EPARs) or ZINL reports. All evidence was aggregated in the estimation of actual treatment cost.ResultsIn the Netherlands, 31 breast cancer drugs are approved (available in 41 different forms). Based on drug list prices Pertuzumab, Trastuzumab Emtansine and Trastuzumab are the most expensive drugs. For 17/41 (41.5%), no evidence on the average treatment length was available in EPARs or ZINL reports. Comparing list prices to the estimated treatment cost per patient resulted in substantial differences in the ranking of expensiveness of the drugs. Overall, estimated treatment costs were highest for Bevacizumab, Pertuzumab and Trastuzumab Emtansine.ConclusionsEstimating treatment costs is far from trivial, given the wide range of evidence sources that need to be synthesized. This complicates rapid and transparent assessment of actual cancer drug treatment cost, which is necessary to focus strategies aiming to limit the increasing healthcare costs. Differences exist in list prices within countries and between countries, thereby influencing the corresponding estimated treatment costs and resulting in list prices having limited value in this context. Therefore, extending standardization in presenting information on costs per cancer drug and implementing real world price estimates in such calculations is highly recommended.

AB - ObjectivesOverall treatment costs in oncology are increasing rapidly due to the increasing availability of expensive drugs. Comparing the costs of currently used drugs and assessing the cost-effectiveness of new drugs requires a transparent overview of actual breast cancer treatment prices. As such an overview is lacking, this study aims to synthesize evidence on the reimbursement and costs to estimate the total treatment cost of expensive breast cancer drugs for the Netherlands.MethodsEvidence on the approval, reimbursement and list prices of expensive breast cancer drugs was identified from the Dutch Administrative Health Authority (ZINL). Data on the average length of treatment and dosing schedules was obtained from European Parliament Assessment Reports (EPARs) or ZINL reports. All evidence was aggregated in the estimation of actual treatment cost.ResultsIn the Netherlands, 31 breast cancer drugs are approved (available in 41 different forms). Based on drug list prices Pertuzumab, Trastuzumab Emtansine and Trastuzumab are the most expensive drugs. For 17/41 (41.5%), no evidence on the average treatment length was available in EPARs or ZINL reports. Comparing list prices to the estimated treatment cost per patient resulted in substantial differences in the ranking of expensiveness of the drugs. Overall, estimated treatment costs were highest for Bevacizumab, Pertuzumab and Trastuzumab Emtansine.ConclusionsEstimating treatment costs is far from trivial, given the wide range of evidence sources that need to be synthesized. This complicates rapid and transparent assessment of actual cancer drug treatment cost, which is necessary to focus strategies aiming to limit the increasing healthcare costs. Differences exist in list prices within countries and between countries, thereby influencing the corresponding estimated treatment costs and resulting in list prices having limited value in this context. Therefore, extending standardization in presenting information on costs per cancer drug and implementing real world price estimates in such calculations is highly recommended.

KW - breast cancer

KW - drugs

KW - treatment cost

KW - Evidence

KW - health economics

U2 - 10.1016/j.jval.2017.08.189

DO - 10.1016/j.jval.2017.08.189

M3 - Conference article

VL - 20

SP - A430-A431

JO - Value in health

JF - Value in health

SN - 1098-3015

IS - 9

ER -